首页/数据集/Data for: Simultaneous determination of plasma methotrexate and 7-hydroxy methotrexate by UHPLC-MS/MS in patients receiving high-dose methotrexate therapy

Data for: Simultaneous determination of plasma methotrexate and 7-hydroxy methotrexate by UHPLC-MS/MS in patients receiving high-dose methotrexate therapy

NIAID Data Ecosystem2026-03-10 收录

多发性硬化症治疗

甲氨蝶呤疗法评估

数据链接：

https://data.mendeley.com/datasets/6tv5nvjx6t 数据链接链接失效反馈

官方服务：

资源简介：

Original of the study.

应用场景：

创建时间：

2018-06-14

多发性硬化症治疗

药物疗效评估

Objective To assess over 3 years of follow-up, the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE)

NIAID Data Ecosystem90

Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

多发性硬化症治疗

神经免疫临床研究

AbstractObjective To assess over 3 years of follow-up, the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension

DataONE2021-11-29 更新40

Number of RRMS patients who initiated a DMD since 2 years before baseline, treatment exposure time, number of relapses, number of patients experiencing a relapse and annualized relapse rate (ARR).

多发性硬化症治疗

疾病修饰疗法疗效评估

Only DMDs used in at least 10 SMSC patients and with at least 1 year of mean follow-up are shown.

NIAID Data Ecosystem10

Relations of cognitive measures with clinical disease parameters in paediatric MS patients.

多发性硬化症治疗

认知功能评估

Relations of cognitive measures with clinical disease parameters in paediatric MS patients.

NIAID Data Ecosystem50

The target proteins that changed significantly during natalizumab treatment.